Renewing Old Ties, Celtic Therapeutics Leads $10 Million Series B For Kolltan
This article was originally published in The Pink Sheet Daily
Executive Summary
Financing includes $1.5 million development option that converts to another Series B if there's no agreement on a co-development program.